Features | VJHemOnc

MDS 2020 highlights

Held in Tel Aviv, Israel, the 2020 MDS Foundation meeting gave key updates on novel drug combinations, the impact of…

COVID-19: a changing time in cancer treatment

The spread of novel betacoronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly escalated to a pandemic…

COVID-19 & HemOnc: an interview with David Marks

The Video Journal of Hematological Oncology (VJHemOnc) interviewed Professor David Marks to discuss the ongoing COVID-19 pandemic currently affecting countries…

Microbiota diversity can predict mortality in patients undergoing allo-HSCT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and curative therapy for a large number of hematologic malignancies. Adverse…

Brentuximab vedotin may hold improved outcomes in frontline stage III/IV classical Hodgkin lymphoma

Updated results from the ECHELON-1 study (NCT01712490) suggest the combination of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) may…

Influencing post-transplant AML outcomes based on MRD status

Recently published in the Journal of Clinical Oncology, work from the Hourigan Lab (National Heart, Lung, and Blood Institute, National…

MPN Advances Day 2019 E-Learning

View e-learning webcasts on myeloproliferative neoplasms here!

iwNHL 2019 e-learning

View e-learning webcasts from iwNHL 2019 here!